Ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacilli in an intensive care unit without carbapenemase-producing Enterobacteriaceae or epidemic Acinetobacter baumannii

References

• Cohen J. Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients. J Antimicrob Chemother 2013;68:490–1.
   PubMed Web of Science ®Google Scholar
• Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013;19:216–28.
   PubMed Web of Science ®Google Scholar
• Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008;13:19045.
   PubMedGoogle Scholar
• Timsit JF, Zahar JR, Chevret S. Attributable mortality of ventilator-associated pneumonia. Curr Opin Crit Care 2011;17:464–71.
   PubMed Web of Science ®Google Scholar
• Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 2013;13:665–71.
   PubMed Web of Science ®Google Scholar
• Agrafiotis M, Siempos II, Ntaidou TK, Falagas ME. Attributable mortality of ventilator-associated pneumonia: a meta-analysis. Int J Tuberc Lung Dis 2011;15:1154–63, i–v.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society–Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare- associated pneumonia. Am J Respir Crit Care Med 2005; 171:388–416.
   PubMedGoogle Scholar
• Torres A, Ewig S, Lode H, Carlet J. Defining, treating and preventing hospital-acquired pneumonia: European perspective. Intensive Care Med 2009;35:9–29.
   PubMed Web of Science ®Google Scholar
• Rosenthal VD, Bijie H, Maki DG, Mehta Y, Apisarnthanarak A, Medeiros EA, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004–2009. Am J Infect Control 2012;40:396–407.
   PubMed Web of Science ®Google Scholar
• Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010;51(Suppl 1):S81–7.
   Google Scholar
• Rello J, Ulldemolins M, Lisboa T, Koulenti D, Manez R, Martin-Loeches I, et al. Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. Eur Respir J 2011;37: 1332–9.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Golan Y, Micek ST, Shorr AF, Restrepo MI. Appraising contemporary strategies to combat multidrug resistant Gram-negative bacterial infections—proceedings and data from the Gram-Negative Resistance Summit. Clin Infect Dis 2011;53(Suppl 2):S33–55.
   PubMedGoogle Scholar
• Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791–8.
   PubMed Web of Science ®Google Scholar
• Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 2012; 25:2–41.
   PubMed Web of Science ®Google Scholar
• Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009;22:582–610.
   PubMed Web of Science ®Google Scholar
• Bowers DR, Liew YX, Lye DC, Kwa AL, Hsu LY, Tam VH. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2013;57:1270–4.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, Von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. [Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration]. Gac Sanit 2009;23:158.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344–9.
   PubMed Web of Science ®Google Scholar
• Armand-Lefevre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppé E, et al. Emergence of imipenem-resistant Gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 2013;57:1488–95.
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol 2010;31:47–53.
   PubMed Web of Science ®Google Scholar
• Pena C, Guzman A, Suarez C, Dominquez MA, Tubau F, Pujol M, et al. Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. Antimicrob Agents Chemother 2007;51:1967–71.
   PubMedGoogle Scholar
• Lepelletier D, Cady A, Caroff N, Marraillac J, Reynaud A, Lucet JC, et al. Imipenem-resistant Pseudomonas aeruginosa gastrointestinal carriage among hospitalized patients: risk factors and resistance mechanisms. Diagn Microbiol Infect Dis 2010;66:1–6.
   PubMedGoogle Scholar
• Vitkauskiene A, Dambrauskiene A, Cerniauskiene K, Rimdeika R, Sakalauskas R. Risk factors and outcomes in patients with carbapenem-resistant Acinetobacter infection. Scand J Infect Dis 2013;45:213–8.
   PubMed Web of Science ®Google Scholar
• Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, et al. Acquisition of multidrug- resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004;38:670–7.
   PubMed Web of Science ®Google Scholar